+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Viral Vector Manufacturing Markets and Technologies Through 2022

  • ID: 4650691
  • Report
  • October 2018
  • Region: Global
  • 255 Pages
  • BCC Research
1 of 5

FEATURED COMPANIES

  • Applied Viromics
  • Boehringer Ingelheim Gmbh
  • GE Healthcare
  • Merck Millipore
  • Pfizer Inc.
  • Synpromics
  • MORE

The scope of this report is broad and covers various types of products available, ongoing research and development in the viral vector vaccine manufacturing market, and potential application sectors across various industries. The viral vector vaccine manufacturing market is broken down by types, application and diseases. Revenue forecasts from 2017 to 2022 are given for each product type, application and diseases with estimated valued derived from the revenue of manufacturers’ total revenues.

The report also includes a discussion of the major players across each regional viral vector vaccine manufacturing market. Further, it explains the major drivers and regional dynamics of the global viral vector vaccine manufacturing market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors in the global viral vector vaccine manufacturing market.

The Report Includes:

  • 145 data tables and 57 additional tables
  • A detailed overview and industry analysis of the global viral vector manufacturing market
  • Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Information on major drivers and regional dynamics of the global viral vector vaccine manufacturing market and current trends within the industry
  • Insight into pipeline products that are manufactured using viral vector tools and technology, and a relevant patent analysis
  • Company profiles of major market players including Advanced Bioscience Laboratories Inc., Boehringer Ingelheim Gmbh, Brammer Bio Llc, Creative Biogene, GE Healthcare, Pfizer Inc., Sanofi SA, and Spark Therapeutics Inc.

Membership Price:

Contact us for membership pricing.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Applied Viromics
  • Boehringer Ingelheim Gmbh
  • GE Healthcare
  • Merck Millipore
  • Pfizer Inc.
  • Synpromics
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Evolution and Transition
  • Market Potential
  • WHO
  • U.S.
  • European Union
  • Australia
  • Japan
  • India
  • China
  • Market Segmentation
  • Segmentation by Type
  • Segmentation by Application
  • Segmentation by Disease
  • Regional Analysis
  • North America
  • Europe
  • Asia-Pacific
  • ROW

Chapter 4 Market Drivers

  • Rising Number of Clinical Trials in Viral Vectors
  • Growing Number of Gene Therapy Candidates
  • Surging Investment in Gene-Therapy-Based R&D Activities
  • Increasing Prevalence of Genetic Disorders and Chronic Diseases

Chapter 5 Market Breakdown by Type

  • Overview
  • Adenoviral Vectors
  • Retroviral Vectors
  • Lentiviral Vectors
  • Adeno-associated Viral Vectors
  • Cytomegalovirus
  • Pox Virus
  • Other Viral Vectors

Chapter 6 Market Breakdown by Disease Application

  • Overview
  • Human Disease Applications
  • Overview
  • Hepatitis
  • Cancer
  • Influenza
  • HIV
  • Tuberculosis
  • Malaria
  • Others
  • Veterinary Disease Applications
  • Avian Influenza
  • Marek's Disease
  • Infectious Bronchitis
  • PPR Disease
  • Others (Rabies, FMD, Swine Influenza, Equine Influenza, Newcastle Disease, etc.)

Chapter 7 Market Breakdown by Application Type

  • Overview
  • Multivalent Viral Vector Vaccines
  • Multipathogen Viral Vector Vaccines

Chapter 8 Market Breakdown by Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Rest of the World (ROW)
  • Latin America
  • Middle East and Africa

Chapter 9 Viral Vector Manufacturing Industry Structure

  • Viral Vector Manufacturing Supply Chain
  • Common Steps Followed in Small-Scale Manufacturing of Adenovirus
  • Step 1: Cell Lysis and Genomic DNA Breakdown
  • Step 2: Clarification
  • Step 3: Concentration
  • Steps 4 and 5: Anion Exchange and Gel Filtration
  • Step 6: Membrane Filtration
  • Companies Involved in Developing Lentiviral Vector Candidates
  • Companies Involved in Developing Adeno-associated Vector (AAV) Candidates
  • Manufacturer Purchasing Criteria
  • Innovation within the Viral Vector Vaccine Manufacturing Industry
  • Competitive Landscape
  • Expansions
  • Collaborations
  • Investments
  • Acquisitions

Chapter 10 Patent Analysis

  • U.S. Patent Analysis
  • European Patent Analysis
  • Japanese Patent Analysis

Chapter 11 Company Profiles

  • Advanced Bioscience Laboratories, Inc.
  • Advanced Biotherapeutics Consulting
  • Applied Viromics
  • Batavia Biosciences
  • Benitec Biopharma
  • Biogen Idec (Now Biogen, Inc.)
  • Biovian
  • Boehringer Ingelheim Gmbh
  • Brammer Bio
  • Cell And Gene Therapy Catapult
  • Ceva Corporate
  • Cobra Biologics (Subsidiary Of Recip Ab)
  • Creative Biogene
  • GE Healthcare
  • Genedetect
  • Genvec Inc. (Subsidiary Of Intrexon Corp.)
  • ID Pharma Co. Ltd.
  • Janssen Pharmaceutical Companies Of Johnson & Johnson
  • Lonza
  • Merck Millipore
  • Miltenyi Biotec
  • Molmed Spa
  • Paragon Bioservices Inc.
  • Pfizer Inc.
  • Sanofi
  • Sementis
  • Spark Therapeutics Inc.
  • Synpromics
  • Valneva
  • Vector Biolabs
  • Vigene Biosciences Inc.
  • Virovek

List of Tables
Summary Table: Global Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 1: Characteristics of Potential Viral Vaccine Vectors
Table 2: Advantages and Disadvantages of Major Viral Vectors
Table 3: Global Market Shares of Viral Vector Vaccine Manufacturing, by Type, 2016 vs. 2022
Table 4: Global Market Shares of Viral Vector Vaccine Manufacturing, by Application Type, 2016 and 2022
Table 5: Global Market Shares of Viral Vector Vaccine Manufacturing, by Disease Segment, 2016 and 2022
Table 6: Vaccine Designs and Strategies for Their Utility Against HIV
Table 7: Global Market Shares of Viral Vector Vaccine Manufacturing, by Region, 2016 and 2022
Table 8: Driver Impact Analysis for Global Viral Vector Vaccine Manufacturing Market
Table 9: List of Clinical Trials with Their Conditions and Interventions
Table 10: Distribution of Diseases Targeted by Prophylactic Gene-Based Vaccines
Table 11: Properties of Various Viral Vectors and Their Application in Gene Therapy
Table 12: Global Incidence of Chronic Diseases, 2005-2030
Table 13: Global Prevalence of Colon Cancer, by Age Group, 2016
Table 14: Global Incidence of HIV Disease, by Region, 2016
Table 15: Various Types of Viral Vectors Used in Gene Therapy and Their Advantages
Table 16: Characteristics of Key Viral Vectors
Table 17: Global Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 18: Global Adenoviral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 19: Global Retroviral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 20: Advantages and Disadvantages of Retroviral Vectors
Table 21: List of Retroviral Vector Vaccines under Development as of March 2018
Table 22: Components of HIV Provirus
Table 23: Clinical Trials Deploying Lentiviral Vectors for Modification of Hematopoietic Stem Cells by Phase
Table 24: Global Lentiviral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 25: Second- versus Third-Generation Lentiviral Systems
Table 26: Selected AAV Vectors with Their Tropisms and Receptors
Table 27: Global Adeno-associated Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 28: Global Cytomegalovirus Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 29: Human Cytomegalovirus Vaccine Candidates in Different Stages of Preclinical and Clinical Development
Table 30: Licensed Fowl Pox Viral-Vectored Veterinary Vaccines
Table 31: Global Pox Virus Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 32: Benefits and Drawbacks of HSV Viral Vectors
Table 33: Global Other Viral Vector Vaccines Manufacturing Market, by Region, Through 2022
Table 34: HSV Proposed Vaccines and Their Characteristics
Table 35: Global Viral Vector Vaccine Manufacturing Market, by Disease Segment, Through 2022
Table 36: Licensed Viral and Bacterial Vaccines for Use in Humans
Table 37: Global Viral Vector Vaccine Manufacturing Market, by Human Disease Application, Through 2022
Table 38: Global Viral Vector Manufacturing Market in Human Disease, by Region, Through 2022
Table 39: Pricing in Gavi Countries: Product-Specific Commitments
Table 40: Estimated New Cases of HAV
Table 41: Number of Death Certificates Listing HAV, HBC and HCV as a Cause of Death, 2015 and 2016
Table 42: Prevalence of HBV Infection (HBSAG) in the General Population, by WHO Region, 2015
Table 43: Leading Sites of Estimated New Cancer Cases in U.S, 2017
Table 44: Virus-Vectored Experimental Influenza Vaccines
Table 45: Some of the Delivery Vectors Evaluated in Clinical Studies for HIV Vaccines
Table 46: People Living with HIV, by Region, 2016
Table 47: Tuberculosis Viral Vector Vaccine Candidates
Table 48: Ongoing Preclinical Development and Clinical Trials on Malaria Vaccines
Table 49: Top 10 Priority Initiatives for Malaria Vaccine Development According to the Malaria Vaccine Technology Roadmap
Table 50: Ongoing Clinical Trials of Vector Vaccines against EVD, As of 2017
Table 51: EVD Cases and Death, by Country
Table 52: Zika Virus Vaccine Development and Ongoing Clinical Trials
Table 53: Licensed Viral-Vectored Veterinary Vaccines
Table 54: Global Estimates of the Growth in Demand for Meat, 2010-2030
Table 55: Global Viral Vector Vaccine Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 56: Global Viral Vector Vaccine Manufacturing Market for Veterinary Disease Application, by Region, Through 2022
Table 57: Avian Influenza Vaccines
Table 58: Global Estimates of Poultry Production
Table 59: Marek’s Disease Vaccines
Table 60: Grants Supporting the Development of Novel Recombinant Adenovirus-Based Vaccine Candidates for Respiratory Diseases in Chickens
Table 61: Global Viral Vector Vaccine Manufacturing Market, by Application, Through 2022
Table 62: Comparison of the Viral Vectors Discussed Based on Specific Vector Characteristics
Table 63: Global Multivalent Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 64: Global Incidence of HIV Disease, by Region, 2015 and 2016
Table 65: Global Incidence of TB, by Region, 2016
Table 66: Global Multipathogen Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 67: Overview of Multivalent/Polyvalent and Multipathogen/Multidisease Viral Vector Vaccine Candidates, by Vector
Table 68: Global Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 69: North American Viral Vector Vaccine Manufacturing Market, by Country, Through 2022
Table 70: North American Viral Vector Manufacturing Market, by Type, Through 2022
Table 71: Cancer Research Funding in the U.S., 2015 and 2016
Table 72: North American Viral Vector Manufacturing Market, by Application Type, Through 2022
Table 73: U.S. Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 74: North American Viral Vector Manufacturing Market, by Disease Segment, Through 2022
Table 75: NIH Funding for CRISPR-Related Research, 2006-2016
Table 76: North American Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
Table 77: New HIV Diagnoses in the U.S., by Age Group, 2016
Table 78: Viral Vector Vaccines in Development in U.S.
Table 79: Canadian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 80: North American Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 81: Confirmed Influenza Cases in Mexico, 2012-2016
Table 82: Mexican Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 83: European Viral Vector Vaccine Manufacturing Market, by Country, Through 2022
Table 84: Losses Due to HPAI Outbreaks in Domestic Birds, by Region, January 2013-January 2018
Table 85: Recent Impact of HPAI in Domestic Birds, by Region, February 2018
Table 86: German Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 87: European Viral Vector Manufacturing Market, by Type, Through 2022
Table 88: U.K. Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 89: European Viral Vector Manufacturing Market, by Application Type, Through 2022
Table 90: HIV/AIDS Statistics in the U.K., 2015
Table 91: People Living with HIV (All Ages) in France, 2000-2016
Table 92: French Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 93: Distribution of the Leading Causes of Death in Women in France, 2017
Table 94: Distribution of the Leading Causes of Death in Men in France, 2017
Table 95: European Viral Vector Manufacturing Market, by Disease Segment, Through 2022
Table 96: European Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
Table 97: HPAI Outbreaks in Poultry and Wild Bird Cases in the E.U., October 2016 - July 2017
Table 98: European Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 99: Spanish Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 100: Number of People in Spain Infected with HIV, by Age, 2000-2016
Table 101: Italian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 102: Italian Poultry Meat Production, 2016
Table 103: Rest of Europe Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 104: Number of People Infected with HIV in Select Countries in the Rest of Europe Region, 2000-2016
Table 105: Asia-Pacific Viral Vector Vaccine Manufacturing Market, by Country, Through 2022
Table 106: Asia-Pacific Viral Vector Manufacturing Market, by Type, Through 2022
Table 107: Chinese Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 108: Asia-Pacific Viral Vector Manufacturing Market, by Application Type, Through 2022
Table 109: Ongoing Preclinical and Clinical Trials of HIV/AIDS Vaccine in China
Table 110: Asia-Pacific Viral Vector Manufacturing Market, by Disease Segment, Through 2022
Table 111: Confirmed Cases of Human Infection with Avian Influenza in China, 2013 and 2016
Table 112: Asia-Pacific Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
Table 113: Indian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 114: Prevalence of Tuberculosis Cases in India, 2016
Table 115: Asia-Pacific Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 116: Ongoing Clinical Trials Related to HIV Vaccines in India
Table 117: Japanese Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 118: Reported Cumulative Number of HIV Cases in Japan, 2012 and 2016
Table 119: Australian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 120: Various Viral Vaccine Vectors Used in AIDS Vaccine Development
Table 121: Number of Newly Diagnosed Cases of HIV Infection in Australia, 2012-2016
Table 122: South Korean Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 123: HPAI Outbreaks in South Korea, 2003-2017
Table 124: Vaccine Strains for Immunization of Chickens against H5N1 HPAIVS
Table 125: Distribution of Causes of Death in South Korea, 2016
Table 126: Rest of APAC Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 127: Leading Causes of Deaths in Singapore, 2014-2016
Table 128: Mortality by Sex and Cause of Death, 2016
Table 129: HIV/AIDS Statistics for Thailand, 2016
Table 130: Ongoing Clinical Trials for Preventive HIV Vaccine Candidates in Thailand
Table 131: Estimated Worldwide Rates of Skin Cancer per Capita
Table 132: Newly Diagnosed HIV Cases in the Philippines, by Age Group, 2016
Table 133: Number of Newly Diagnosed HIV Cases per Day in the Philippines, 2008-2017
Table 134: ROW Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 135: ROW Viral Vector Manufacturing Market, by Type, Through 2022
Table 136: Latin American Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 137: Poultry Consumption across ROW Countries, 2017
Table 138: ROW Viral Vector Manufacturing Market by Application Type Through 2022
Table 139: Top 10 Causes of Deaths in Cuba and Percentage Change from 2005 to 2016
Table 140: Middle East and African Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 141: ROW Viral Vector Manufacturing Market, by Disease Segment, 2017-2022
Table 142: Characteristics of the Priority Diseases Identified in the WHO R&D Blueprint, Revised, 2017
Table 143: ROW Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
Table 144: ROW Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 145: Viral Vector Overview
Table 146: Related Impurities to be Eliminated, by Downstream Processing
Table 147: Viral Vector Manufacturing Suppliers
Table 148: List of Some of the Viral Vector Producers
Table 149: List of Company Expansion
Table 150: List of Collaborations
Table 151: List of Investments
Table 152: List of Acquisitions
Table 153: U.S. Viral Vector Vaccine Manufacturing Patents, 2015-May 2018
Table 154: European Viral Vector Vaccine Manufacturing Patents, 2015-May 2018
Table 155: Japanese Viral Vector Vaccine Manufacturing Patents, 2015-May 2018
Table 156: Advanced BioScience Laboratories Product Portfolio
Table 157: Advanced BioScience Laboratories Recent Developments, 2015-April 2018
Table 158: Advanced Biotherapeutics Consulting Product Portfolio
Table 159: Applied Viromics Product Portfolio
Table 160: Batavia Biosciences Product Portfolio
Table 161: Batavia Bioscience Recent Developments, 2015-April 2018
Table 162: Benitec Biopharma Product Portfolio
Table 163: Biogen Product Portfolio
Table 164: Biogen Recent Developments, 2015-April 2018
Table 165: Biovian Product Portfolio
Table 166: Boehringer Ingelheim Product Portfolio
Table 167: Brammer Bio Product Portfolio
Table 168: Brammer Bio Recent Developments, 2015-April 2018
Table 169: Cell and Gene Therapy Catapult Product Portfolio
Table 170: Cell and Gene Therapy Catapult Recent Developments, 2015 - April 2018
Table 171: Ceva Product Portfolio
Table 172: Cobra Biologics Product Portfolio
Table 173: Cobra Biologics Recent Developments, 2015 - April 2018
Table 174: Creative Biogene Product Portfolio
Table 175: GE Healthcare Product Portfolio
Table 176: GeneDetect Product Portfolio
Table 177: GenVec Product Portfolio
Table 178: ID Pharma Product Portfolio
Table 179: Janssen Product Portfolio
Table 180: Janssen Recent Developments, 2015 - April 2018
Table 181: Lonza Group Product Portfolio
Table 182: Lonza Group Recent Developments, 2015 - April 2018
Table 183: Merck Millipore Product Portfolio
Table 184: Merck Millipore Recent Developments, 2015 - April 2018
Table 185: Miltenyi Biotec Product Portfolio
Table 186: MolMed Product Portfolio
Table 187: Paragon Bioservices Product Portfolio
Table 188: Paragon Bioservices Recent Developments, 2015 - April 2018
Table 189: Pfizer Product Portfolio
Table 190: Pfizer Recent Developments, 2015 - April 2018
Table 191: Sanofi Product Portfolio
Table 192: Sementis Product Portfolio
Table 193: Spark Therapeutics Product Portfolio
Table 194: Spark Therapeutics Recent Developments, 2015 - April 2018
Table 195: Synpromics Product Portfolio
Table 196: Synpromics Recent Developments, 2015 - April 2018
Table 197: Valneva Product Portfolio
Table 198: Vector Biolabs Product Portfolio
Table 199: Vigene Biosciences Product Portfolio
Table 200: Vigene Biosciences Recent Developments, 2015 - April 2018
Table 201: Virovek Product Portfolio

List of Figures
Summary Figure: Global Viral Vector Vaccine Manufacturing Market, by Type, 2017-2022
Figure 1: Notable Vaccine Advancements
Figure 2: Vaccine Research Cycle
Figure 3: WHO Mandatory Steps for Vaccine Approval
Figure 4: FDA Stages of Vaccine Review and Regulation
Figure 5: EMA Stages of Vaccine Review and Regulation
Figure 6: MHLW Stages of Vaccine Review and Regulation
Figure 7: Vaccine Approval Process in India
Figure 8: Life Cycle of Virus in Cells
Figure 9: Key Properties of Viral Vector
Figure 10: Global Market Shares of Viral Vector Vaccine Manufacturing, by Type, 2016 and 2022
Figure 11: Working of an Ad-Vector Vaccine
Figure 12: Role of CMV in Immunosenesce of Humans
Figure 13: Global Market Shares of Viral Vector Vaccine Manufacturing, by Application Type, 2016 - 2022
Figure 14: Global Market Shares of Viral Vector Vaccine Manufacturing, by Disease Segment, 2016 and 2022
Figure 15: Global Market Shares of Viral Vector Vaccine Manufacturing, by Region, 2016 and 2022
Figure 16: Distribution of Diseases Targeted by Prophylactic Gene-Based Vaccines
Figure 17: Global Incidence of Chronic Diseases 2005-2030
Figure 18: Global Prevalence of Colon Cancer, by Age Group, 2016
Figure 19: Global Incidence of HIV Disease, by Region, 2016
Figure 20: Structure of Third-Generation Lentiviral Vectors
Figure 21: Prevalence of HBV Infection (HBSAG) in the General Population, by WHO Region, 2015
Figure 22: People Living with HIV, by Region, 2016
Figure 23: EVD Cases and Death, by Country
Figure 24: Global Estimates of the Growth in Demand for Meat, 2010-2030
Figure 25: Global Shares of Demand for Meat, 2010 and 2030
Figure 26: Global Estimates of Poultry Production
Figure 27: Schematic Overview of Multipathogen/Multidisease and Multivalent/Polyvalent Viral Vector Vaccines
Figure 28: Global Incidence of HIV Disease, by Region, 2015 and 2016
Figure 29: Comparative Analysis of Regional Market Shares, 2016 vs. 2022
Figure 30: New HIV Diagnoses in the U.S., by Age Group, 2016
Figure 31: Confirmed Influenza Cases in Mexico, 2012-2016
Figure 32: Losses Due to HPAI Outbreaks in Domestic Birds, by Region, January 2013-January 2018
Figure 33: People Living with HIV (All Ages) in France, 2000-2016
Figure 34: Distribution of the Leading Causes of Death in Women in France, 2017
Figure 35: Distribution of the Leading Causes of Death in Men in France, 2017
Figure 36: Number of People in Spain Infected with HIV, by Age, 2000-2016
Figure 37: Italian Poultry Meat Production, 2016
Figure 38: Number of People Infected with HIV in Select Countries in the Rest of Europe Region, 2000-2016
Figure 39: Confirmed Human Infection with Avian Influenza in China, 2013 and 2016
Figure 40: Reported Cumulative Number of HIV Cases in Japan, 2012 and 2016
Figure 41: Number of Newly Diagnosed Cases of HIV Infection in Australia, 2012-2016
Figure 42: Distribution of Causes of Death in South Korea, 2016
Figure 43: Estimated Worldwide Rates of Skin Cancer per Capita
Figure 44: Newly Diagnosed HIV Cases in the Philippines, by Age Group, 2016
Figure 45: Number of Newly Diagnosed HIV Cases per Day in the Philippines, 2008-2017
Figure 46: Poultry Consumption Across ROW Countries, 2017
Figure 47: Features of Vectors
Figure 48: Key Properties of Viral Vectors
Figure 49: Common Viral-Vector Manufacturing Process
Figure 50: Viral Vector Manufacturing Process
Figure 51: Adenovirus Manufacturing Process
Figure 52: Viral-Vector Vaccine Manufacturing Industry
Figure 53: Level of Impact of Manufacturer Purchasing Criteria, 2018-2022
Figure 54: Shares of Competitive Landscape, 2015-2018

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Applied Viromics
  • Boehringer Ingelheim Gmbh
  • GE Healthcare
  • Merck Millipore
  • Pfizer Inc.
  • Synpromics
  • MORE

Rising prevalence of human chronic diseases and veterinary diseases across the globe is propelling the adoption of viral vector vaccines because vaccines are recognized to be the most cost-effective and efficient medium. According to World Health Organization (WHO), the number of patients suffering from chronic diseases such as cancer, chronic respiratory diseases, cardiovascular diseases and others was noted at about 130 million people in 2005 and is expected to reach around 173 million by 2030. Moreover, according to the WHO “World Health Statistics” report, cardiovascular disease, cancer and chronic respiratory disease caused around 17.9 million, 9 million and 3.8 million, respectively, which in total accounts for 75% of noncommunicable disease deaths across the globe. In addition, according to Avert Organization (U.K.), in 2016, approximately 36.7 million people were found to be suffering from human immunodeficiency virus (HIV), and 1 million people died due to HIV-related diseases in 2016. Furthermore, according to the report, in 2016, 5.1 million new cases of acquired immune deficiency syndrome (AIDS) were registered in Asia-Pacific, compared with 0.23 million in North Africa and the Middle East. Moreover, Sub-Saharan Africa registered the highest prevalence of AIDS, with more than 19 million infected by HIV in 2016.

Moreover, increasing veterinary diseases such as avian influenza, Marek’s disease, infectious bronchitis Peste des Petits Ruminants (PPR) disease and others are also becoming a global concern. According to the U.S. Department of Health and Human Services, the number of rabid dogs increased from 59 in 2014 to 67 in 2015. Moreover, according to the report, 92.4% of rabies cases were found in wild animals. In 2015, according to the American Veterinary Medical Association, 5,508 cases of rabies have been reported in U.S., including 5,088 wildlife cases. Therefore, rising cases of veterinary and human chronic diseases is propelling the viral vector vaccine manufacturing market. Companies and government institutes are performing continuous research activities to develop viral-vector-based vaccines. Viral vector vaccines are more cost-effective and efficient than conventional vaccines. Viral-vector-based vaccines have the ability to enrich immunogenicity without an adjuvant and induce a vigorous cytotoxic T lymphocyte (CTL) response to abolish virus-infected cells. For instance, Royal Free Hospital (U.K.) and Oxford University Hospital (U.K.), in 2017, were involved in Phase I clinical trial of the adeno-associated viral vector (FLT180a) in patients with hemophilia B. Moreover, in 2017, the Orthopaedic Hemophilia Treatment Center (California), Medical University of South Carolina (MUSC), (South Carolina), Gulf States Hemophilia and Thrombophilia Center (Texas) were involved in a Phase II trial of BAX 888 drug, an adeno-associated virus serotype 8 (AAV8) vector expressing B-domain-deleted factor VIII (BDD-FVIII) in severe hemophilia A subjects administered a single intravenous infusion.

The report provides an analysis based on each market segment, which includes by type, disease and application. The global viral vector vaccine manufacturing market by type is further segmented on the basis of adenoviral vectors, retroviral vectors, lentiviral vectors, adeno-associated viral vectors, cytomegalovirus, pox virus and other viral vectors.

Note: Product cover images may vary from those shown
5 of 5
  • Advanced Bioscience Laboratories, Inc.
  • Advanced Biotherapeutics Consulting
  • Applied Viromics
  • Batavia Biosciences
  • Benitec Biopharma
  • Biogen Idec (Now Biogen, Inc.)
  • Biovian
  • Boehringer Ingelheim Gmbh
  • Brammer Bio
  • Cell And Gene Therapy Catapult
  • Ceva Corporate
  • Cobra Biologics (Subsidiary Of Recip Ab)
  • Creative Biogene
  • GE Healthcare
  • Genedetect
  • Genvec Inc. (Subsidiary Of Intrexon Corp.)
  • ID Pharma Co. Ltd.
  • Janssen Pharmaceutical Companies Of Johnson & Johnson
  • Lonza
  • Merck Millipore
  • Miltenyi Biotec
  • Molmed Spa
  • Paragon Bioservices Inc.
  • Pfizer Inc.
  • Sanofi
  • Sementis
  • Spark Therapeutics Inc.
  • Synpromics
  • Valneva
  • Vector Biolabs
  • Vigene Biosciences Inc.
  • Virovek
Note: Product cover images may vary from those shown
Adroll
adroll